Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing the clinical researchers include not only the ability to add additional ...

IIdentification of relevant mutations, determination of tumor mutational burden (TMB) and microsatellite (MS) status are paramount to precision oncology research and the Oncomine Comprehensive Assay ...

Recipients’ research advances future development of oncology diagnostics, the impact of DNA quality on ovarian cancer outcomes and molecular diagnosis with T cell receptor convergence CARLSBAD, Calif.

Ion Torrent Oncomine Myeloid MRD Assays (RUO) are the first NGS-based tests to offer simultaneous DNA and RNA analysis for myeloid MRD assessment CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher ...